bioMérieux – First-Half 2018 Results

• Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
  
  • €1,169 million in sales
  • Up 3.1% as reported
• Contributive operating income before non-recurring items up 7% to €185 million, or 15.8% of sales
• 2018 financial targets revised:
  
  • Organic growth in sales of around 9.5%, at constant exchange rates and scope of consolidation
  • Contributive operating income before non-recurring items of between €340 million and €350 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux performed well in the first half of the year, combining solid organic sales growth and a sharp increase in earnings. Given this momentum, we are now in a position to revise our full-year financial objectives upward while continuing our ambitious investments in innovation and in bioMérieux’s future development, to best serve our clients, patients and our public health mission.”

Marcy l’Étoile (France), September 5, 2018 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2018. The statements had been reviewed by the Statutory Auditors.